Chemomab Therapeutics (CMMB) Free Cash Flow Growth (5y) (2022 - 2023)

Chemomab Therapeutics (CMMB) Free Cash Flow Growth (5y) (2022 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Chemomab Therapeutics 729.63 Mn 719.26 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 1.03%
Sep 30, 2023 4.40%
Jun 30, 2023 -31.28%
Mar 31, 2023 -21.84%
Dec 31, 2022 -25.32%